Ligand Pharmaceuticals, Inc.
LGNDZ
Other OTC0.00
USD
+0.00
- -
Ligand Pharmaceuticals, Inc.
LGNDZ
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ligand Pharmaceuticals, Inc. (LGND) is a biopharmaceutical company that develops, acquires and invests in royalty-generating technologies and assets to support the discovery, development and commercialization of high-value medicines; it manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, encompassing more than 90 partnered commercial and development-stage programs across disease areas including cancer, kidney disease, diabetes, nonalcoholic steatohepatitis and rare conditions, with economic rights to over 30 commercial programs marketed in more than 70 countries. The company maintains and licenses its proprietary Captisol and NITRICIL technology platforms, which enable improved drug solubility, stability and tunable dosing for applications in areas such as oncology (Kyprolis, Evomela), infectious diseases (Noxafil-IV, Vaxneuvance), cardiovascular (Nexterone) and dermatology (ZELSUVMI); it also offers HepDirect, LTP, BEPro and Pelican Expression technologies through alliances with leading pharmaceutical partners including Amgen, Merck, Pfizer, Gilead Sciences, Takeda and Baxter International. Founded in 1987 and headquartered in San Diego, California, Ligand generates revenue primarily from royalties, milestones and licensing fees targeting global biopharmaceutical markets. In recent developments, Ligand completed the acquisition of APEIRON Biologics AG for $100 million in July 2024, adding royalties and milestones on early-stage immuno-oncology assets while investing $4 million in APEIRON spin-off invIOs Holding; it launched Pelthos Therapeutics in April 2024 to commercialize ZELSUVMI (acquired via NITRICIL from Novan in 2023), receiving a $5 million milestone upon launch and a 13% royalty on worldwide sales, followed by Pelthos' merger with Channel Therapeutics in 2025 supported by an $18 million Ligand investment. Ligand led a $75 million financing in Castle Creek Biosciences for D-Fi in dystrophic epidermolysis bullosa, securing a high-single-digit royalty, and committed to a $40 million investment with Medtronic in Orchestra BioMed's AVIM and Virtue SAB cardiovascular therapies, which hold multiple FDA breakthrough designations; additionally, partner SQ Innovation received FDA approval for Lasix ONYU, and Merck's acquisition of Verona Pharma is poised to accelerate Ohtuvayre commercialization in COPD. These transactions underscore Ligand's strategy of partnering with capital providers and strategics to maximize asset value through equity stakes and royalties.